Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Idurote 2 Sulfatase (Alpha L Idurote Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Overview
Idurote 2 Sulfatase (Alpha L Idurote Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Idurote 2 Sulfatase (Alpha L Idurote Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Idurote 2 Sulfatase (Alpha L Idurote Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Companies Involved in Therapeutics Development
AVROBIO Inc
Bioasis Technologies Inc
Deli Therapeutics Inc
Esteve Pharmaceuticals SA
GC Pharma
Homology Medicines Inc
JCR Pharmaceuticals Co Ltd
RegenxBio Inc
Takeda Pharmaceutical Co Ltd
Idurote 2 Sulfatase (Alpha L Idurote Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Drug Profiles
AVRRD-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DNL-310 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EGT-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Idurote 2 Sulfatase for Mucopolysaccharidosis II - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HMI-203 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
idursulfase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
idursulfase beta - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pabifusp alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RGX-121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
xB-3008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Idurote 2 Sulfatase (Alpha L Idurote Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Dormant Products
Idurote 2 Sulfatase (Alpha L Idurote Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Discontinued Products
Idurote 2 Sulfatase (Alpha L Idurote Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Product Development Milestones
Featured News & Press Releases
May 14, 2021: REGENXBIO presents additiol positive interim data from phase I/II trial of RGX-121 for the treatment of MPS II (Hunter Syndrome) at American Society of Gene and Cell Therapy’s 24th Annual Meeting
Apr 14, 2021: Regenxbio announces dosing of first patient in cohort 3 of phase I/II trial of RGX-121 for the treatment of MPS II (Hunter syndrome)
Mar 23, 2021: JCR Pharmaceuticals announces approval of IZCARGO (pabifusp alfa) for treatment of MPS II (Hunter syndrome) in Japan
Mar 11, 2021: Deli Therapeutics announces fast track desigtion granted by the U.S. FDA to ETV:IDS (DNL310) for the treatment of patients with Hunter syndrome (MPS II)
Mar 03, 2021: GC Green Cross to ship’Hunterase ICV’ in Japan
Feb 16, 2021: JCR Pharmaceuticals presents research at WORLDSymposium 2021 showing potential benefits of JR-141 (pabifusp alfa) in patients with MPS II (Hunter Syndrome)
Feb 12, 2021: Deli Therapeutics reports positive three-month data from phase 1/2 study with ETV:IDS (DNL310) in patients with hunter syndrome (MPS II)
Feb 10, 2021: JCR Pharmaceuticals receives FDA IND clearance to initiate global phase 3 clinical trial of JR-141 for Mucopolysaccharidosis Type II (Hunter Syndrome)
Feb 10, 2021: FDA grants fast track desigtion for JR-141 for the treatment of mucopolysaccharidosis type II (Hunter syndrome)
Feb 08, 2021: Homology Medicines announces first presentation of data with HMI-203 in vivo gene therapy development candidate for Hunter syndrome
Feb 08, 2021: Regenxbio presents additiol positive interim data from Phase I/II Trial Of Rgx-121 For The Treatment Of MPS II (Hunter Syndrome) at 17th Annual Worldsymposium 2021
Feb 05, 2021: Deli Therapeutics to present new data on ETV:IDS (DNL310) for the potential treatment of Hunter syndrome at WORLDSymposium
Jan 27, 2021: JR-141 (Pabifusp Alfa) for Hunter syndrome: Notice on the publication of the results of non-clinical trials in Molecular Therapy
Jan 22, 2021: Announcing marketing approval for Hunterase ICV Injection 15 mg, the world’s first enzyme replacement therapy for Mucopolysaccharidosis Type II (Hunter Syndrome) administered by ICV injection
Dec 23, 2020: JCR files Hunter Syndrome drug in Brazil
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by AVROBIO Inc, 2021
Pipeline by Bioasis Technologies Inc, 2021
Pipeline by Denali Therapeutics Inc, 2021
Pipeline by Esteve Pharmaceuticals SA, 2021
Pipeline by GC Pharma, 2021
Pipeline by Homology Medicines Inc, 2021
Pipeline by JCR Pharmaceuticals Co Ltd, 2021
Pipeline by RegenxBio Inc, 2021
Pipeline by Takeda Pharmaceutical Co Ltd, 2021
Dormant Projects, 2021
Discontinued Products, 2021